信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002390 信邦制药

已收盘 10-20 15:00:00

{"stockData":{"symbol":"002390","market":"SZ","secType":"STK","nameCN":"信邦制药","latestPrice":2.85,"timestamp":1792479828000,"preClose":2.87,"halted":0,"volume":16464161,"delay":0,"changeRate":-0.007,"floatShares":1928000000,"shares":1944000000,"eps":0.058,"marketStatus":"已收盘","change":-0.02,"latestTime":"10-20 15:00:00","open":2.86,"high":2.89,"low":2.83,"amount":47085800,"amplitude":0.0209,"askPrice":2.86,"askSize":2153,"bidPrice":2.85,"bidSize":4147,"shortable":0,"etf":0,"ttmEps":0.058,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":5,"adr":0,"adjPreClose":2.87,"symbolType":"stock","openAndCloseTimeList":[[1792459800000,1792467000000],[1792472400000,1792479600000]],"highLimit":3.16,"lowLimit":2.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1943851868,"isCdr":false,"pbRate":0.83,"roa":"--","peRate":49.137931,"roe":"1.46%","epsLYR":0.0634,"committee":-0.040945,"marketValue":5540000000,"turnoverRate":0.0085,"status":1,"floatMarketCap":5494000000},"requestUrl":"/m/hq/s/002390","defaultTab":"news","newsList":[{"id":"2674002632","title":"股市必读：信邦制药新发布《关于控股子公司涉及诉讼的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674002632","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674002632?lang=zh_cn&edition=full","pubTime":"2026-10-09 02:42","pubTimestamp":1791484932,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月8日主力资金净流出255.83万元，占总成交额3.87%；  公司公告汇总：控股子公司科开医药因单位行贿罪被一审判处罚金400万元，占公司最近一期归母净利润的3.33%。公司公告汇总关于控股子公司涉及诉讼的进展公告贵州信邦制药股份有限公司于2026年10月8日发布公告，其控股子公司贵州科开医药有限公司因单位行贿罪被贵州省开阳县人民法院判处罚金人民币400万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900002476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0239","002390","BK0028","BK0146","BK0096","BK0056","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673121730","title":"股市必读：信邦制药新发布《关于控股子公司涉及诉讼的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673121730","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673121730?lang=zh_cn&edition=full","pubTime":"2026-10-08 02:13","pubTimestamp":1791396788,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，信邦制药报收于2.96元，上涨1.37%，换手率1.04%，成交量20.04万手，成交额5919.7万元。当日关注点交易信息汇总：9月30日主力资金净流出452.88万元，占总成交额7.65%；  公司公告汇总：控股子公司科开医药因单位行贿罪被一审判处罚金400万元，占公司最近一期归母净利润的3.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0146","BK0096","BK0114","BK0056","002390","BK0028","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671269767","title":"信邦制药（002390）9月28日主力资金净买入1007.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269767?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:08","pubTimestamp":1790644103,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，信邦制药报收于2.94元，上涨1.03%，换手率1.07%，成交量20.64万手，成交额6012.78万元。近5日资金流向一览见下表：信邦制药融资融券信息显示，融资方面，当日融资买入285.61万元，融资偿还383.5万元，融资净偿还97.89万元。信邦制药主营业务：医疗服务、医药流通及医药制造。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900008272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0056","BK0096","BK0004","BK0146","BK0114","002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663171470","title":"信邦制药营收连续下滑，上半年扣非净利润降幅近30%，“三驾马车”集体失速","url":"https://stock-news.laohu8.com/highlight/detail?id=2663171470","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663171470?lang=zh_cn&edition=full","pubTime":"2026-08-29 22:12","pubTimestamp":1788012720,"startTime":"0","endTime":"0","summary":"来源：深圳商报","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-29/doc-inipzani3427034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662669030","title":"信邦制药(002390)6月30日股东户数6.57万户，较上期减少6.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662669030","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662669030?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:47","pubTimestamp":1787910477,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信邦制药披露，截至2026年6月30日公司股东户数为6.57万户，较3月31日减少4778.0户，减幅为6.78%。在中药行业个股中，信邦制药股东户数高于行业平均水平，截至6月30日，中药行业平均股东户数为5.16万户。从股价来看，2026年3月31日至2026年6月30日，信邦制药区间跌幅为18.89%，在此期间股东户数减少4778.0户，减幅为6.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0056","002390","BK0028","BK0146","BK0239","BK0096","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662367055","title":"信邦制药2026年半年报：经营现金流改善，营收净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2662367055","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662367055?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:08","pubTimestamp":1787890101,"startTime":"0","endTime":"0","summary":"财报数据显示，报告期公司实现营业收入24.67亿元，同比下降13.29%；归母净利润0.99亿元，同比下降7.10%；扣非归母净利润0.77亿元，同比下降28.13%。从业务结构看，医药流通仍是公司最大收入来源，报告期实现营收17.46亿元，占比59.17%，但受药品集采降价及厂家配送权调整影响，该板块营收同比下降18.33%，毛利率下降1.92个百分点至7.08%。医疗服务板块实现营收7.30亿元，占比24.76%，同比下降7.65%，毛利率微升0.87个百分点至11.23%，主要得益于医院精细化运营及特色科室建设。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787882626298319619","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159399","002390","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662858970","title":"信邦制药(002390.SZ)发布半年度业绩，归母净利润9958.63万元，同比下降7.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662858970","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662858970?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:02","pubTimestamp":1787839365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信邦制药 发布2026年半年度报告，报告期内，公司实现营业收入24.67亿元，较上年同期下降13.29%;归属于上市公司股东的净利润9958.63万元，较上年同期下降7.1%;归属于上市公司股东的扣除非经常性损益的净利润7663.61万元，较上年同期下降28.13%;基本每股收益0.0525元。报告期内，公司医疗服务实现营业收入7.3亿元，较上年同期下降7.65%，其中肿瘤医院3.93亿元，综合医院3.38亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647669374","title":"信邦制药：近五年实施权益分派七次，累积派发现金红利（含税）6.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647669374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647669374?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:51","pubTimestamp":1782737488,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药06月29日在投资者关系平台上答复投资者关心的问题。公司前期已通过实施股份回购、现金分红等方式以维护全体投资者利益，近五年实施完成两次股份回购计划，累计成交总金额6.55亿元；近五年实施权益分派七次，累积派发现金红利（含税）6.32亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900037847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","002390","BK0239","BK0056","BK0146","BK0028","BK0096","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635884807","title":"信邦制药（002390）披露2025年度股东会决议公告，5月13日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635884807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635884807?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:09","pubTimestamp":1778666946,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，信邦制药报收于3.28元，较前一交易日下跌0.61%，最新总市值为63.76亿元。该股当日开盘3.3元，最高3.32元，最低3.26元，成交额达6918.27万元，换手率为1.1%。公司于近日披露《2025年度股东会决议的公告》。会议由公司第九届董事会召集，董事长安吉女士主持，出席股东及授权代表共314名，代表有表决权股份496,416,812股，占公司总股本的26.1767%。所有提案均获表决通过，其中部分议案获中小投资者多数同意。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","002390","BK0146","BK0239","BK0056","BK0004","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634236792","title":"股市必读：信邦制药（002390）5月11日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634236792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634236792?lang=zh_cn&edition=full","pubTime":"2026-05-12 01:13","pubTimestamp":1778519588,"startTime":"0","endTime":"0","summary":"截至2026年5月11日收盘，信邦制药报收于3.36元，上涨0.9%，换手率1.65%，成交量31.81万手，成交额1.06亿元。公司 2025 年营业收入下滑主要原因系医院及医药批发业务的经营规模受市场环境、行业政策等因素影响有所收缩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200001295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0146","BK0004","BK0028","002390","BK0096","BK0114","BK0239","BK0056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632725526","title":"每周股票复盘：信邦制药（002390）Q1净利增17.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632725526","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632725526?lang=zh_cn&edition=full","pubTime":"2026-05-03 04:10","pubTimestamp":1777752619,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，信邦制药报收于3.37元，较上周的3.16元上涨6.65%。本周，信邦制药4月30日盘中最高价报3.4元。股本股东变化股东户数变动截至2026年3月31日，信邦制药股东户数为7.04万户，较2025年12月31日减少3458.0户，减幅4.68%。业绩披露要点财务报告信邦制药2026年一季报显示，一季度主营收入12.63亿元，同比下降12.34%；归母净利润4865.65万元，同比上升17.97%；扣非净利润4714.52万元，同比上升14.78%；负债率17.06%，投资收益103.48万元，财务费用268.55万元，毛利率16.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0239","BK0028","BK0114","BK0096","BK0146","BK0056","002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631015596","title":"信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631015596","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631015596?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:53","pubTimestamp":1777456399,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信邦制药披露，截至2026年3月31日公司股东户数为7.04万户，较12月31日减少3458.0户，减幅为4.68%。在中药行业个股中，信邦制药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.36万户。从股价来看，2025年12月31日至2026年3月31日，信邦制药区间涨幅为1.86%，在此期间股东户数减少3458.0户，减幅为4.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900056212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0146","002390","BK0004","BK0239","BK0096","BK0056","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306508","title":"图解信邦制药一季报：第一季度单季净利润同比增长17.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306508","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630306508?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:25","pubTimestamp":1777375518,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药2026年一季报显示，一季度公司主营收入12.63亿元，同比下降12.34%；归母净利润4865.65万元，同比上升17.97%；扣非净利润4714.52万元，同比上升14.78%；负债率17.06%，投资收益103.48万元，财务费用268.55万元，毛利率16.2%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800055384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629841982","title":"信邦制药：公司本报告期非经常性损益的主要构成为投资收益与子公司税率变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2629841982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629841982?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:48","pubTimestamp":1777034888,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药04月23日在投资者关系平台上答复投资者关心的问题。扣除非经常性损益的净利润较上年同期减少的主要原因为①非经常性损益本报告期为净收益，而上一年度为净损失②报告期计提信用减值损失及资产减值损失较上一年度增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400062344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0056","002390","BK0096","BK0239","BK0146","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629889548","title":"信邦制药：公司2025年综合毛利率较去年同期略有上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2629889548","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629889548?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:51","pubTimestamp":1776934269,"startTime":"0","endTime":"0","summary":"证券之星消息，信邦制药04月23日在投资者关系平台上答复投资者关心的问题。信邦制药回复：您好，公司2025年综合毛利率较去年同期略有上升。公司及子公司的涉诉事项处于审理阶段，其结果存在不确定性，可能对公司的生产经营带来不利影响，目前公司及子公司的生产经营活动正常开展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300045699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0056","002390","BK0114","BK0146","BK0028","BK0239","BK0096","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629081767","title":"信邦制药(002390)3月31日股东户数7.04万户，较上期减少4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629081767","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629081767?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:17","pubTimestamp":1776763026,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信邦制药披露，截至2026年3月31日公司股东户数为7.04万户，较12月31日减少3458.0户，减幅为4.68%。在中药行业个股中，信邦制药股东户数高于行业平均水平，截至3月31日，中药行业平均股东户数为5.36万户。从股价来看，2025年12月31日至2026年3月31日，信邦制药区间涨幅为1.86%，在此期间股东户数减少3458.0户，减幅为4.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100038975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0056","002390","BK0028","BK0146","BK0239","BK0096","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628741249","title":"信邦制药最新公告：2025年净利润同比增长18.65%拟10派0.6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628741249","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628741249?lang=zh_cn&edition=full","pubTime":"2026-04-20 18:20","pubTimestamp":1776680410,"startTime":"0","endTime":"0","summary":"信邦制药(002390.SZ)披露年报，2025年实现营业收入56.2亿元，同比下降6.84%；归母净利润1.2亿元，同比增长18.65%；基本每股收益0.06元。公司拟每10股派发现金红利0.6元(含税)。报告期内，归母净利润增长的主要原因为营业外支出事项较上年度减少，公司综合毛利率略有上升。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000028304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002390"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792530014502,"stockEarnings":[{"period":"1week","weight":-0.0273},{"period":"1month","weight":-0.021},{"period":"3month","weight":-0.0176},{"period":"6month","weight":-0.0747},{"period":"1year","weight":-0.2341},{"period":"ytd","weight":-0.0892}],"compareEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0874},{"period":"1year","weight":-0.0333},{"period":"ytd","weight":-0.0588}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州信邦制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"65664人(较上一季度减少6.78%)","perCapita":"29358股","listingDate":"2010-04-16","address":"贵州省黔南布依族苗族自治州罗甸县龙坪镇信邦大道48号","registeredCapital":"194385万元","survey":"　　贵州信邦制药股份有限公司的主营业务是医疗服务、医药流通、医药制造。公司的主要产品是益心舒胶囊、脉血康胶囊、关节克痹丸（独家品种）、银杏叶片、六味安消胶囊、贞芪扶正胶囊等药品、中药饮片及大健康产品。","listedPrice":33},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信邦制药(002390)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信邦制药,002390,信邦制药股票,信邦制药股票老虎,信邦制药股票老虎国际,信邦制药行情,信邦制药股票行情,信邦制药股价,信邦制药股市,信邦制药股票价格,信邦制药股票交易,信邦制药股票购买,信邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信邦制药(002390)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信邦制药(002390)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}